Concurrently, CD28, glucocorticoid-induced TNFR-related protein (GITR), and OX40 (CD134) promote T cell expansion, also representing primary immunotherapy targets for HCC (Llovet et al., 2022). Here, TNFRSF18 is linked to hepatocellular carcinoma.